Physician profile
Russell Dodds
NPI 1013989086
$2,352.02
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.77 · 2020: $31.02 · 2021: $72.88 · 2022: $2,206.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomerieux INC | $2,111.60 | 2022 | |
| Merck Sharp & Dohme LLC | $54.70 | 2021-2022 | |
| Roche Diagnostics Corporation | $27.21 | 2022 | |
| Seagen INC. | $26.72 | 2019-2021 | |
| Deciphera Pharmaceuticals INC. | $23.90 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $18.47 | 2020 | |
| Myriad Genetic Laboratories, INC. | $18.42 | 2021 | |
| Eisai INC. | $17.27 | 2022 | |
| Amgen INC. | $16.55 | 2019 | |
| Janssen Biotech, INC. | $12.60 | 2022 | |
| Incyte Corporation | $12.55 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $12.03 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Dodds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.